Received Jun 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | 92NN2 | RA |
Lymphadenopathy worsened; swelling in his neck; swelling in his right arm; This non-serious case was reported by a pharmacist via sales rep and described the occurrence of lymphadenopathy in a 73-year-old male patient who received Herpes zoster (Shingrix) (batch number 92NN2, expiry date 30-MAR-2027) for prophylaxis. On 28-MAY-2025, the patient received the 1st dose of Shingrix (right arm). On 01-JUN-2025, 4 days after receiving Shingrix, the patient experienced lymphadenopathy (Verbatim: Lymphadenopathy worsened), neck swelling (Verbatim: swelling in his neck) and swelling arm (Verbatim: swelling in his right arm). The patient was treated with clindamycin. The outcome of the lymphadenopathy, neck swelling and swelling arm were resolving. The reporter considered the lymphadenopathy, neck swelling and swelling arm to be related to Shingrix. The company considered the lymphadenopathy, neck swelling and swelling arm to be related to Shingrix. Additional Information: GSK Receipt Date: 03-JUN-2025 The reporter stated that the patient who received Shingrix and noticed swelling in his right arm and neck on 1st June upon awakening and went to the ER (emergency room). Emergency room attributed to Shingrix. Lymphadenopathy was reported as worsened, and it was not serious. Given 5 day course clindamycin to the patient in emergency room, on 3rd June (on the day of reporting) patient was seen by PCP (primary care physician). Patient reported symptoms were improving. No other products were received by the patient.